Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

230 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.
Gastaldelli A, Balas B, Ratner R, Rosenstock J, Charbonnel B, Bolli GB, Boldrin M, Balena R. Gastaldelli A, et al. Among authors: ratner r. Diabetes Obes Metab. 2014 Feb;16(2):170-8. doi: 10.1111/dom.12192. Epub 2013 Aug 22. Diabetes Obes Metab. 2014. PMID: 23911196 Clinical Trial.
Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096).
Ratner R, Wynne A, Nakhle S, Brusco O, Vlajnic A, Rendell M. Ratner R, et al. Diabetes Obes Metab. 2011 Dec;13(12):1142-8. doi: 10.1111/j.1463-1326.2011.01478.x. Diabetes Obes Metab. 2011. PMID: 21812890 Free PMC article. Clinical Trial.
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.
Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Garber A, et al. Among authors: ratner r. Diabetes Obes Metab. 2011 Apr;13(4):348-56. doi: 10.1111/j.1463-1326.2010.01356.x. Diabetes Obes Metab. 2011. PMID: 21205128 Free PMC article. Clinical Trial.
Approach to the patient with prediabetes.
Aroda VR, Ratner R. Aroda VR, et al. Among authors: ratner r. J Clin Endocrinol Metab. 2008 Sep;93(9):3259-65. doi: 10.1210/jc.2008-1091. J Clin Endocrinol Metab. 2008. PMID: 18772457 Review.
Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.
Zinman B, DeVries JH, Bode B, Russell-Jones D, Leiter LA, Moses A, Johansen T, Ratner R; NN1250-3724 (BEGIN:EASY AM) and NN1250-3718 (BEGIN:EASY PM) Trial Investigators. Zinman B, et al. Among authors: ratner r. Lancet Diabetes Endocrinol. 2013 Oct;1(2):123-31. doi: 10.1016/S2213-8587(13)70013-5. Epub 2013 Jul 9. Lancet Diabetes Endocrinol. 2013. PMID: 24622318 Clinical Trial.
230 results